The Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional) funding from the National Institutes of Health (NIH) supports translational and clinical research to
- advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact;
- enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and
- discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children.
The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities. An R21 grant application need not have extensive background material or preliminary information. Applications are open to researchers in the USA and worldwide. Applicants may apply for up to 275,000 USD in direct costs for up to 2 years.
Opportunity number: PAR-23-131
Letters of intent are due: January 5, 2024.
Applications are due: February 5, 2024.
February 5, 2024